Cargando…

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

BACKGROUND: Although several clinical trials have suggested that postoperative adjuvant chemotherapy can improve survival of patients with gastric cancer, the optimal treatment duration has not been studied. This retrospective analysis evaluated the outcomes of patients with gastric cancer treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Jing-lei, Li, Xin, Qu, Xiu-juan, Zhu, Zhi-tu, Zhou, Li-zhong, Teng, Yue-e, Zhang, Jing-dong, Jin, Bo, Zhao, Ming-fang, Yu, Ping, Liu, Yun-peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873471/ https://www.ncbi.nlm.nih.gov/pubmed/24386161 http://dx.doi.org/10.1371/journal.pone.0083196

Ejemplares similares

Optimal Duration of Adjuvant Chemotherapy for Gastric Cancer: Might Less Be More?
por: Han, Hye Sook
Publicado: (2022)

Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
por: Scheithauer, W., et al.
Publicado: (1998)

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
por: Collienne, Maike, et al.
Publicado: (2020)

Update of Adjuvant Chemotherapy for Resected Gastric Cancer
por: Oh, Sang Cheul
Publicado: (2012)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical Study
por: Xu, Yan, et al.
Publicado: (2021)

Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy
por: Zhou, Yi-Xin, et al.
Publicado: (2018)

Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
por: Hisashige, Akinori, et al.
Publicado: (2013)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study()
por: Meng, Changting, et al.
Publicado: (2014)

An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer
por: Yan, Hongfei, et al.
Publicado: (2021)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
por: Fu, Jin Ye, et al.
Publicado: (2022)

Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China
por: Tan, Chongqing, et al.
Publicado: (2013)

A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy()
por: Wang, Jin, et al.
Publicado: (2016)

Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer
por: Yuan, Shu-Qiang, et al.
Publicado: (2017)

Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors
por: Liu, Rui-qing, et al.
Publicado: (2013)

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
por: Ju, Wu‐tong, et al.
Publicado: (2021)

Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
por: Xu, Jian-Bo, et al.
Publicado: (2017)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

Cbl-b Enhances Sensitivity to 5-Fluorouracil via EGFR- and Mitochondria-Mediated Pathways in Gastric Cancer Cells
por: Feng, Dan, et al.
Publicado: (2013)

Prognostic Model Based on Systemic Inflammatory Response and Clinicopathological Factors to Predict Outcome of Patients with Node-Negative Gastric Cancer
por: Qu, Jing-lei, et al.
Publicado: (2015)

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer
por: YANG, LIN, et al.
Publicado: (2015)

Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer
por: Ahn, Geon Tae, et al.
Publicado: (2020)

Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2002)

Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer
por: Fu, Xing-Li, et al.
Publicado: (2017)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
por: Kim, Seong-Geun, et al.
Publicado: (2016)

D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016)

Adjuvant therapy in resectable gastric cancer.
por: Bleiberg, H., et al.
Publicado: (1992)

A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
por: Ge, Long, et al.
Publicado: (2019)

Three Biomarkers Predict Gastric Cancer Patients' Susceptibility To Fluorouracil-based Chemotherapy
por: Pan, Jiaomeng, et al.
Publicado: (2019)

Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer: a propensity-matched analysis
por: Quan, RenCui, et al.
Publicado: (2016)

Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival
por: Jiang, Zhi-Nong, et al.
Publicado: (2021)

Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer
por: OCHIAI, TAKUMI, et al.
Publicado: (2014)

Systematic Review With Network Meta-Analysis: Adjuvant Chemotherapy for Resected Colorectal Liver Metastases
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
por: Hadzitheodorou, Christina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5b73mr6q534ibl4cmud2nmj7t8